PITTSBURGH, Oct 13, 2020 (GLOBE NEWSWIRE) – NeuBase Therapeutics, Inc. (NASDAQ: NBSE) (“NeuBase” or the “Company”), a biotechnology company accelerating the genetic revolution using a new class of synthetic drugs, announced the addition of Peter Nielsen, Ph.D. to its Scientific Council. Dr. Nielsen, the leading inventor of peptide nucleic acid (PNA) technology, brings extensive genetic medicine experience to NeuBase as the company optimizes its PATrOL ™ therapies and moves them to the clinic.
“We are honored to welcome Dr. Nielsen, a transformational leader in genetics and genomic technologies, to the NeuBase Scientific Advisory Board. His unique perspective gained during his distinctive career will undoubtedly provide valuable insight and complement our renowned team of experts, ”said Dietrich A. Stephan, Ph.D., CEO of NeuBase. “We believe that our new class of synthetic drugs, which are based on the elegant scaffolding chemistry invented by Dr. Nielsen, has the potential to change the therapeutic landscape for many diseases, both common and rare. We look forward to leveraging his unparalleled knowledge as we continue to advance our PATrOL platform under the leadership of our outstanding group of scientific advisors. “
Dr Nielsen added, “NeuBase’s PNA technology is among the first to be advanced in the development of therapeutic applications, and I am delighted to be a part of the company’s revolution. I look forward to working with the team and providing advice as NeuBase advances its first-class medications. “
Dr Peter Nielsen is a leading expert in gene targeting, RNA interference and chemical replication and translation and was one of the inventors of PNAs in 1991. He is currently a professor at the University of Copenhagen where his laboratory is located. focuses on PNAs when it comes to drugs. discovery, gene targeting, antisense principles, cellular and in vivo delivery and administration of biopharmaceuticals. He is the co-author of more than 400 scientific articles and journals as well as more than 20 patents and patent applications, and he serves on the advisory boards of four scientific journals. In addition to his esteemed academic career, Dr Nielsen is the co-founder of two biotechnology companies in Denmark and is a member of EMBO and the Danish Academy of Technical Sciences. He got his doctorate. in 1980 from the University of Copenhagen.
About NeuBase Therapeutics, Inc.
NeuBase is accelerating the genetic revolution by using a new class of synthetic drugs. The PATrOL ™ therapies designed by NeuBase center on its proprietary drug scaffolding to treat genetic diseases at the source by combining the highly targeted approach of traditional genetic therapies with the broad delivery capabilities of small molecule organs. By initially focusing on silencing disease-causing mutations in debilitating neurological, neuromuscular and oncological disorders, NeuBase is committed to redefining medicine for the millions of patients with common and rare diseases. To learn more, visit www.neubasetherapeutics.com.
Use of forward-looking statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act. These forward-looking statements are distinguished by the use of words such as “will”, “would”, “anticipate”, “expect”, “believe”, “designed”, “plan” or “intend” , terms and similar references to future periods. These opinions involve risks and uncertainties that are difficult to predict and, therefore, our actual results may differ materially from the results discussed in our forward-looking statements. Our forward-looking statements contained herein speak only as of the date of this press release. Factors or events that we cannot predict, including risk factors contained in our documents filed with the United States Securities and Exchange Commission, may cause our actual results to differ from those expressed in the statements. prospective. The Company may not actually carry out the plans, achieve the intentions or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on such forward-looking statements. Since these statements deal with future events and are based on the Company’s current expectations, they are subject to various risks and uncertainties, and the actual results, performance or achievements of the Company could differ materially from those described or under- heard by statements in this press. publication, including: the Company’s plans to develop and market its product candidates; the timing of the launch of clinical trials planned by the Company; the timing of the availability of the Company’s clinical trial data; the timing of any investigational new drug request or new drug request; the Company’s plans to research, develop and market its current and future product candidates; the clinical utility, potential benefits and market acceptance of the Company’s product candidates; the Company’s marketing, marketing and manufacturing capabilities and strategy; global health conditions, including the impact of COVID-19; the Company’s ability to protect its intellectual property position; and the requirement for additional capital to continue to advance these product candidates, which may not be available on favorable terms or at all, as well as the risk factors contained in our files with the State Securities and Exchange Commission. -United. Unless otherwise provided by law, the Company disclaims any intention or obligation to update or revise forward-looking statements, which are only valid as of the date hereof, whether as a result of new information, events or future circumstances or otherwise.
Contact for NeuBase investors:
LifeSci Advisors, LLC
OP: (617) 430-7576
NeuBase media contact:
Cait Williamson, Ph.D.
OP: (646) 751-4366